Nearly 60% of people with advanced melanoma were found to have reduced tumor sizes after being subjected to ipilimumab and nivolumab.
An international trial on 945 patients found that treatment with ipilimumab and nivolumab stopped the cancer advancing for nearly a year.
Melanoma
Melanoma of the skin is a dangerous type of skin cancer that usually appears as a cancerous mole due to exposure to the sun's damaging UV rays.
Advertisement
The immune system is a powerful defense against infection. Cancer, which is a corrupted version of healthy tissue, can take advantage of brakes which are naturally built in to stop attacks on its own tissues and deplete the immune system.
Ipilimumab, which was approved as an advanced melanoma treatment by the UK's health service last year, and nivolumab both take the brakes off.
Dr. James Larkin, a consultant at the Royal Marsden Hospital said, "By giving these drugs together you are effectively taking two brakes off the immune system rather than one so the immune system is able to recognise tumors it wasn't previously recognizing and react to that and destroy them."
But the great hope is these immunotherapies will prove to be effective treatments for a wide range of cancer types.
Source: Medindia
Dr. James Larkin, a consultant at the Royal Marsden Hospital said, "By giving these drugs together you are effectively taking two brakes off the immune system rather than one so the immune system is able to recognise tumors it wasn't previously recognizing and react to that and destroy them."
But the great hope is these immunotherapies will prove to be effective treatments for a wide range of cancer types.
Source: Medindia
Red Hair Pigment May Increase Risk of Melanoma, Skin Cancer
Recent animal studies suggest that pigment responsible for red hair in fair-skinned people might play a role in triggering skin cancer.
Advertisement
 Vemurafenib Improves Survival in Advanced Malignant MelanomaVemurafenib is a new oral drug that improves survival in advanced malignant melanoma. | Advertisement
|
Ipilimumab With Dacarbazine Improves Survival in Metastatic Melanoma
Ipilimumab in combination with dacarbazine improves survival in metastatic melanoma: Results of a Phase III study.
Advertisement
Recommended Reading
Latest Clinical Trials News
Early and late Chronic Traumatic Encephalopathy (CTE) disease processes in the post-mortem brains were similar in some ways but dramatically different in others.
Researchers have developed a new hydrogel biomaterial that adheres to heart tissue to prevent scar tissue formation after a heart attack and its consequences.
The oil extracted from Cannabidiol (CBD) present in cannabis (marijuana) does not lower pain scores after common treatment for urinary stones.
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found it prompted immune response and was safe.
Using routine brain imaging tests data, a new deep-learning algorithm was able to detect Alzheimer's disease with 90.2% accuracy.